Clinical evaluation of IDAS II, a new electronic device enabling drug adherence monitoring.

Details

Ressource 1Download: serval:BIB_E5FA08C59DB3.P001 (129.74 [Ko])
State: Public
Version: author
License: Not specified
It was possible to publish this article open access thanks to a Swiss National Licence with the publisher.
Serval ID
serval:BIB_E5FA08C59DB3
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Clinical evaluation of IDAS II, a new electronic device enabling drug adherence monitoring.
Journal
European Journal of Clinical Pharmacology
Author(s)
Santschi V., Wuerzner G., Schneider M.P., Bugnon O., Burnier M.
ISSN
0031-6970 (Print)
ISSN-L
0031-6970
Publication state
Published
Issued date
09/2007
Volume
63
Number
2
Pages
1179-1184
Language
english
Notes
Publication types: Comparative Study ; Evaluation Studies ; Journal Article ; Randomized Controlled Trial ; Research Support, Non-U.S. Gov't Publication Status: ppublish
Abstract
OBJECTIVE: The goal of this study was to evaluate clinically the acceptability of the IDAS II (Intelligent Drug Administration System), a new electronic device that enables drug adherence monitoring.
METHODS: IDAS II was compared to another electronic monitor, the Medication Event Monitoring System (MEMS) in a randomised two-way cross-over study involving 24 hypertensive patients treated with irbesartan. Patients used each device for 2 months. The main parameter of evaluation was the patients' opinion on both devices. Rates of adherence and blood pressure were also assessed.
RESULTS: Most patients considered both devices to be reliable reminders (IDAS II: 75%;MEMS: 84%, p = ns). Ten patients (42%) preferred the MEMS, while 11 (46%) preferred the IDAS II; three (12%) expressed no preference. Patients found the MEMS device easier to use than the IDAS device (p < 0.001) but appreciated the IDAS blister packs better than the MEMS bulk packaging (p < 0.01). Over the 4-month period, the median "taking adherence" was excellent (99.2%) and comparable with both devices. However, the regularity of drug intake timing was higher with the IDAS II (p < 0.01).
CONCLUSION: IDAS II, a new electronic device enabling drug adherence monitoring without reconditioning of the drugs appears to be a well-accepted device. Overall, practicability and acceptability of the IDAS II and the MEMS device were similar. Thus, IDAS II could be a useful tool for the management of long-term therapies.
Keywords
Adult, Aged, Antihypertensive Agents/administration & dosage, Antihypertensive Agents/therapeutic use, Biphenyl Compounds/administration & dosage, Biphenyl Compounds/therapeutic use, Cross-Sectional Studies, Drug Monitoring/instrumentation, Drug Monitoring/psychology, Equipment Design, Equipment and Supplies, Female, Humans, Hypertension/drug therapy, Male, Middle Aged, Patient Compliance, Questionnaires, Tetrazoles/administration & dosage, Tetrazoles/therapeutic use
Pubmed
Web of science
Open Access
Yes
Create date
28/01/2008 11:42
Last modification date
01/10/2019 6:20
Usage data